Oncorus Inc. (ONCR) News

Oncorus Inc. (ONCR): $1.29

0.09 (+7.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 407

in industry

Filter ONCR News Items

ONCR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ONCR News From Around the Web

Below are the latest news stories about Oncorus Inc that investors may wish to consider to help them evaluate ONCR as an investment opportunity.

Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing beginning Monday, January 10, 2022 at 7:00am ET under the Investors & Media

Yahoo | January 3, 2022

Head to Head Contrast: Kronos Bio (NASDAQ:KRON) versus Oncorus (NASDAQ:ONCR)

Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of []

Dakota Financial News | December 12, 2021

Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Oncorus, Inc. (NASDAQ:ONCR) by 43.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,493 shares of the companys stock after acquiring an additional 25,477 shares during the period. Charles Schwab Investment Management [] The post Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc. appeared first on ETF Daily News .

ETF Daily News | November 29, 2021

One Oncorus, Inc. (NASDAQ:ONCR) insider upped their stake in the previous year

Insiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more...

Yahoo | November 29, 2021

Oncorus to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference: A corporate presentation will be available on-demand starting Monday, November 22nd at 10:00 a.m

Yahoo | November 23, 2021

JPMorgan Chase & Co. Increases Position in Oncorus, Inc. (NASDAQ:ONCR)

JPMorgan Chase & Co. lifted its position in shares of Oncorus, Inc. (NASDAQ:ONCR) by 164.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,841 shares of the companys stock after buying an additional 4,881 shares during the quarter. JPMorgan Chase & Co.s holdings []

Transcript Daily | November 18, 2021

Oncorus, Inc. (NASDAQ:ONCR) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in shares of Oncorus, Inc. (NASDAQ:ONCR) by 46.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 663,669 shares of the companys stock after buying an additional 208,980 shares during the period. Vanguard Group Inc. owned []

Transcript Daily | November 17, 2021

Oncorus to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Jefferies London Healthcare Conference.

Intrado Digital Media | November 17, 2021

Oncorus, Inc. (NASDAQ:ONCR) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in Oncorus, Inc. (NASDAQ:ONCR) by 91.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 248,352 shares of the companys stock after buying an additional 118,625 shares during the period. Geode Capital Management LLC owned 0.96% of Oncorus []

Transcript Daily | November 16, 2021

Oncorus Inc. (NASDAQ: ONCR) Drops -45.59% In Early Trade; What Lies Ahead?

Oncorus Inc. (NASDAQ:ONCR) price closed lower on Friday, November 12, dropping -45.59% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Stocks Register | November 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5759 seconds.